Genetic & Molecular Testing Billing 2026: Codes, MolDX and Denial Prevention

By Rcmaxis Revenue Cycle Team  ·  August 2026  ·  15 min read

Genetic and molecular testing billing sits in a different category of complexity than almost any other lab specialty, and it isn't close. You're not choosing between a handful of CPT codes — you're navigating a five-tier code architecture, a separate proprietary identifier requirement most labs outside this niche have never heard of, and a payer prior authorization landscape that changes policy faster than most billing teams can track it. Get any one layer wrong and the claim doesn't just get denied, it often gets denied for a reason your coding team didn't even know existed.

This matters more in 2026 than it did even two years ago. Medicare's own spending data shows genetic testing now accounts for nearly half of all Part B laboratory dollars, and OIG has responded by opening a dedicated audit specifically targeting genetic test billing patterns. If your practice or lab orders, performs, or bills molecular diagnostics, this is the year to get the fundamentals locked down.

The Five-Tier Code Structure: Tier 1, Tier 2, GSP, MAAA and PLA

Molecular pathology billing runs on a code architecture that doesn't map cleanly onto how most billers think about CPT. Instead of one code per test, you're choosing between five different code families depending on what kind of test was run and how established it is.

A few real examples make the distinction concrete. 81288 is a Tier 1 code for MLH1 promoter methylation analysis, used in Lynch syndrome workups. 81415/81416 cover exome sequencing for the proband and each comparator exome. 81525 is the MAAA code for the Oncotype DX colon recurrence score — you're billing the algorithm's output, not the individual analytes that feed into it. And 0001U was the very first PLA code ever issued, covering a proprietary blood-group genotyping assay. Over time, high-volume Tier 2 codes get promoted into their own dedicated Tier 1 codes as AMA reviews utilization — which means a code you used correctly last year might need to change this year purely because of coding maintenance, not because the test changed.

MolDX and the Z-Code Requirement

Here's the requirement that catches labs and ordering practices off guard more than any single CPT rule: if your MAC participates in the MolDX program — and MolDX now sets molecular diagnostic policy across 28 states through multiple MACs, not just its originating administrator Palmetto GBA — every molecular test needs a unique DEX Z-Code registered in the Diagnostics Exchange online registry, reported alongside the CPT or HCPCS code on the claim.

The reason this exists is straightforward once you see it: a generic Tier 2 or GSP code doesn't tell the payer which specific proprietary test was actually run. The Z-Code does. Without one — or without a completed MolDX Technical Assessment establishing the test's analytical validity, clinical validity, and clinical utility — the MAC has no way to verify the service, and the claim gets denied for registration failure. This is a separate failure mode from medical necessity denial, and it trips up labs that have never had to deal with Medicare's identification-layer requirements before.

Medical Necessity, Ordering Rules and Prior Authorization

CMS's baseline documentation rule for lab services applies fully to genetic testing: the treating physician who's actually managing the patient's condition has to order the test, and while a signed written order isn't strictly mandatory, the physician's intent to order needs to be documented in the medical record. Phone orders need to be documented on both the ordering office side and the testing facility side. None of this is unique to genetic testing, but genetic testing gets audited on it more often because the tests are expensive and the ordering chain is longer — genetic counselors, specialists, and primary care physicians are often all involved in a single testing decision.

Where genetic testing billing gets genuinely payer-specific is prior authorization. UnitedHealthcare runs a Genetic and Molecular Lab Testing Notification/Prior Authorization program across its commercial, Individual Exchange, and Community Plan lines in specific states, administered through lab benefit manager Avalon Healthcare Solutions. Notably, UHC actually rolled back some of this in 2025 — effective January 1, 2025, it discontinued coverage for certain codes and removed prior authorization requirements for multi-panel pharmacogenetic codes on select commercial and all Exchange plans, which is a rare example of a payer loosening genetic testing restrictions rather than tightening them.

Anthem/Elevance moved the opposite direction. Its Genetic Testing Solution program shifted from post-payment review to pre-service prior authorization, and GenomeWeb has reported labs and genetic counselors seeing denial rates as high as 80 percent on hereditary cancer panel claims after the policy took effect — though that figure comes from GenomeWeb's reporting on provider complaints, not a number Anthem itself has published. Concert Genetics provides the digital infrastructure behind Anthem's program and several other payers' genetic testing benefit management, running test ordering, coding, and payment-integrity analytics through a Preferred Laboratory Network model.

OIG's 2026 Genetic Testing Audit and Enforcement History

OIG published a report in January 2026 — Total Medicare Part B Spending on Lab Tests Rose in 2024, Driven by Increased Spending on Genetic Tests — that put real numbers behind what a lot of RCM teams already suspected. Total 2024 Medicare Part B lab spending hit $8.4 billion, up 5 percent year over year, and genetic test spending alone reached $3.6 billion, or 43 percent of that total. That's happening even as fewer beneficiaries overall are getting lab tests — meaning the growth is coming from higher cost per test, not more testing volume. The top 25 tests by spend accounted for $4.1 billion, nearly half of all lab spending.

That report is why OIG opened a new, currently active Work Plan project in June 2026 — Trends and Vulnerabilities in Genetic Tests Covered Under Medicare Part B — specifically targeting genetic test billing patterns. This isn't a historical audit reference; it's a live, ongoing OIG focus area as of this year.

Common Genetic Testing Denial Patterns and Fixes